retatrutide phase 2 nejm 2023 weight loss percent 48 weeks Retatrutide, an Amazing Future for retatrutide phase 2 trial obesity

Failure to do so may lead to a variety of health issues, including anemia, fatigue, muscle weakness, intestinal problems, nerve damage, and mood disturbances

Semaglutide vs tirzepatide: syringe dosage differences If you are comparing semaglutide with tirzepatide or considering switching between them, understanding the syringe dosage differences matters

Nicotinamide riboside supplementation does not alter whole-body or skeletal muscle metabolic responses to a single bout of endurance exercise

Als2/alsin deficiency in neurons leads to mild defects in macropinocytosis and axonal growth

Patino E, Bhatia D, Vance SZ, Antypiuk A, Uni R, Campbell C, Castillo CG, Jaouni S, Vinchi F, Choi ME et al